Comparing Mounjaro with other weight management options is more useful when you look at named treatments and real evidence rather than broad claims about different types of treatment. This guide compares Mounjaro with Wegovy (semaglutide), orlistat, lifestyle changes alone, and other weight loss injections. It also explains how the Mounjaro pen works, including some of the steps involved in using it.
There is no single treatment that is right for everyone. Clinical trial results suggest that Mounjaro can lead to greater average weight loss than some of its main alternatives, but individual results can vary. The right option depends on your health, eligibility, medical history and preferences. A prescriber can help you decide which treatment may be suitable for you.
Key things to know
- In a direct clinical trial, tirzepatide (Mounjaro) resulted in greater average weight loss than semaglutide (Wegovy) at the doses and time points studied
- The Mounjaro pen is not fully automated. You attach a fresh needle and prime the pen before each dose
- Orlistat works differently from Mounjaro by reducing the amount of dietary fat absorbed in the gut rather than mainly affecting appetite
- NHS access to Mounjaro is available for eligible patients, but the current criteria are narrower than those used for private prescribing
- Both online and GP prescribing require an appropriate clinical assessment. The main differences are usually how the consultation is arranged and how quickly it can be completed
Mounjaro vs Wegovy: What the Evidence Shows
This is one of the comparisons people often want to make, and there is direct clinical evidence available. The SURMOUNT 5 trial compared tirzepatide (Mounjaro) directly with semaglutide (Wegovy) in the same study, rather than comparing results from separate trials.
Mounjaro contains tirzepatide, which acts on both GIP and GLP 1 receptors. Wegovy contains semaglutide, which acts on the GLP 1 receptor. Both medicines can affect appetite and food intake, but they work through different mechanisms.
In SURMOUNT 5, participants taking tirzepatide lost an average of 20.2% of their body weight, compared with 13.7% for those taking semaglutide at the doses and time points studied.
Other clinical trials have also reported substantial average weight loss with both medicines. However, results from separate studies should not be compared directly because the studies can have different participants, treatment periods and methods.
This does not mean that Wegovy is ineffective. An average weight loss of 13.7% in SURMOUNT 5 was still clinically meaningful. Some people may also respond differently to each medicine. Your prescriber can consider your individual circumstances when deciding whether Mounjaro, Wegovy or another treatment may be appropriate.
Mounjaro vs Orlistat: A Fundamentally Different Mechanism
Orlistat works differently from Mounjaro. It reduces the amount of dietary fat absorbed by the gut, so its effect is linked to the amount of fat in the food you eat. Unlike Mounjaro, it does not work mainly by affecting appetite through GIP and GLP 1 pathways.
Mounjaro, Wegovy and Saxenda are injectable treatments, while orlistat is taken by mouth.
Orlistat can be prescribed through the NHS for eligible patients and is also available privately. Alli is an over the counter version containing a lower dose of orlistat.
Clinical studies generally show more modest average weight loss with orlistat than with newer medicines such as tirzepatide and semaglutide. However, results vary between individuals, and the most suitable option depends on your medical history, preferences and treatment needs.
Orlistat may be worth discussing if you prefer a treatment that does not involve an injection or if a GLP 1 based medicine is not suitable for you. A clinician can explain how the different options compare for your circumstances.
Mounjaro vs Lifestyle Only Approaches
Lifestyle changes, including a balanced diet and regular physical activity, remain an important part of weight management. Mounjaro is intended to be used alongside a reduced calorie diet and increased physical activity, rather than as a replacement for them.
The realistic comparison is therefore not medication versus lifestyle changes. Instead, it is whether adding medication may provide extra support when lifestyle changes alone have not led to enough weight loss.
Lifestyle only approaches do not involve medicine related costs or medicine side effects. They can also help you build habits that remain important for long term weight management, whether or not you use medication.
However, weight loss from lifestyle changes can vary significantly between people. Some people may find that changes to diet and physical activity alone are not enough to achieve the weight loss they are aiming for. In these situations, a healthcare professional may discuss whether a prescription treatment could be appropriate.
Comparison at a Glance
| Option | Mechanism | Typical average result |
|---|---|---|
| Mounjaro (tirzepatide) | GIP and GLP 1 receptor agonist, can reduce appetite | 20.2% (SURMOUNT 5, compared with the semaglutide arm) |
| Wegovy (semaglutide) | GLP 1 receptor agonist, can reduce appetite | 13.7% (SURMOUNT 5, semaglutide arm) |
| Orlistat | Reduces dietary fat absorption in the gut | Generally more modest than GLP 1 and GIP medicines |
| Lifestyle only | Diet and physical activity | Varies significantly between individuals and approaches |
The figures shown above are average results from clinical research and should not be taken as a prediction of how much weight you will lose. Individual results can vary.
What the Mounjaro KwikPen Actually Involves
It is worth being clear about how the Mounjaro KwikPen works, as it is sometimes described as being more automated than it actually is.
The KwikPen is a multi dose device containing four weekly doses. It is not a single use auto injector. Mounjaro and Wegovy are both taken once a week, while Saxenda is taken once a day.
The Mounjaro KwikPen does not come with a needle permanently attached. You attach a new, sterile needle before each dose and remove it after the injection.
Before each injection, you need to prime the pen according to the instructions provided with your medicine. This helps make sure the pen is ready to deliver the dose. You then inject the medicine as instructed by your healthcare professional or the product instructions.
Rotating your injection site may help reduce local injection site problems such as irritation or discomfort. Your prescriber or pharmacist can show you how to use the pen correctly if you are unsure.
The process is straightforward for many people once they become familiar with it, but it does involve several hands on steps. Knowing this before starting treatment can help you understand what to expect.
Online vs GP Prescribing: What Actually Differs
Both online and GP prescribing involve a clinical assessment before Mounjaro treatment can be supplied. A healthcare professional may review your medical history, current medicines, health conditions and whether Mounjaro is suitable for you. Mounjaro is a prescription only medicine and cannot be bought over the counter.
The main difference is how the consultation is arranged. An online service may allow you to complete an assessment remotely, while a GP consultation takes place through your NHS GP practice. The time needed for either route can vary.
Private online prescribing does not mean that the clinical assessment is skipped. A suitable prescriber still needs to decide whether treatment is appropriate before issuing a prescription. Some providers may also offer discreet delivery if treatment is prescribed.
NHS access to Mounjaro is currently being introduced in phases and is subject to specific eligibility criteria. These criteria can be narrower than those used by private services. A private prescription is still subject to a clinical assessment and should only be issued when the prescriber considers the treatment appropriate.
A Note on Insurance Coverage
UK private medical insurance policies often exclude weight management and obesity treatment from standard cover. However, policies can differ.
If insurance coverage is important to you, check your policy or speak directly with your insurer before assuming that weight loss treatment will or will not be covered.
Comparing Side Effects Across Options
Mounjaro, Wegovy and Saxenda can cause some similar side effects because they affect related pathways in the body. Common side effects can include nausea, vomiting and diarrhoea. These effects may be more noticeable for some people when treatment starts or when the dose is increased.
Orlistat has a different side effect profile because it works in the gut. Gastrointestinal effects such as oily stools, changes in bowel movements and urgency can occur. These effects can be more noticeable after meals containing more fat.
More serious side effects are possible with prescription weight management medicines, although they are less common. For example, inflammation of the pancreas has been reported with medicines in this group. Your prescriber will consider your medical history and other medicines when assessing the risks.
Mounjaro should not be used by people who have had a serious allergic reaction to tirzepatide or any of its ingredients. Low blood sugar can also occur, particularly when Mounjaro is used with certain diabetes medicines such as insulin or sulfonylureas.
Lifestyle only approaches do not have medicine related side effects, but major or poorly planned dietary changes can still cause problems, particularly if your diet becomes too restrictive. A balanced approach is important.
No treatment is completely risk free. The best option depends on the potential benefits and risks for you. If you experience worrying or severe symptoms while taking a medicine, seek medical advice.
Comparing Ongoing Support and Monitoring
Whichever option you choose, ongoing support can be important. Prescription treatments such as Mounjaro and Wegovy usually involve follow up reviews where a prescriber can assess your response, side effects and whether your current dose remains appropriate.
For people using Mounjaro for type 2 diabetes, reviews may also include blood glucose management and consideration of other diabetes medicines. Mounjaro can help lower blood glucose levels in people with type 2 diabetes, so your wider diabetes care may need to be considered when treatment is reviewed.
Depending on your circumstances, your healthcare professional may also recommend blood tests or other health checks. This can help them assess whether continuing treatment is appropriate.
Orlistat may also require follow up, particularly because following a lower fat diet can help reduce gastrointestinal side effects and support treatment. Lifestyle only approaches can also benefit from support, such as a structured weight management programme, advice from a dietitian or regular self monitoring.
The type and frequency of monitoring will depend on the treatment you are using and your individual health needs.
Who Each Option Might Suit
Mounjaro may be suitable for adults with a BMI of 30 or above, or a BMI of 27 or above with a weight related health condition, subject to the licensed indication and an appropriate clinical assessment. Your prescriber will also check for reasons why Mounjaro may not be suitable for you.
Wegovy may be suitable for some people who meet the relevant eligibility criteria and need prescription support with weight management. Your prescriber may consider Wegovy or another treatment depending on your medical history and individual circumstances.
Orlistat may be an option for people who prefer a medicine taken by mouth or who have specific reasons why another weight management medicine may not be suitable.
Lifestyle changes remain an important part of weight management and may be appropriate on their own, particularly for people who do not meet the criteria for prescription treatment.
NHS access to Mounjaro is subject to separate eligibility criteria and is being introduced in phases. Current NHS criteria can include a higher BMI together with several weight related health conditions. These can include high blood pressure, type 2 diabetes, obstructive sleep apnoea and cardiovascular disease.
A clinical assessment is the best way to find out whether Mounjaro, Wegovy, orlistat or another approach may be suitable for you. This comparison is intended to help you understand the options, not to replace personalised medical advice.
Long Term Sustainability
Whichever approach you choose, long term weight management usually involves ongoing attention rather than a fixed treatment period with a guaranteed end result.
Clinical research with medicines such as tirzepatide and semaglutide has found that some people regain weight after stopping treatment. Continuing treatment has been associated with better maintenance of weight loss in clinical studies. However, individual responses vary.
Obesity and excess weight can be long term health concerns, which means weight management may also need to be considered over the longer term. Your prescriber can review whether continuing treatment remains appropriate based on your progress, health and treatment goals.
Lifestyle habits also remain important. A balanced diet and regular physical activity can support weight management during and after treatment. However, maintaining these habits does not guarantee that weight will remain unchanged.
Orlistat only works while you are taking the medicine and eating food containing dietary fat. Prescription medicines such as Mounjaro and Wegovy also need to be taken as prescribed if they are being used to support ongoing weight management.
This does not mean that you are committed to one treatment forever. Your treatment can be reviewed over time, and your prescriber can discuss whether continuing, changing or stopping treatment is appropriate for you.
Getting Started with EverydayMeds
If Mounjaro seems like a suitable option based on this comparison, starting treatment begins with a free online clinical consultation, reviewed by our UK registered prescribers as part of a clinical assessment before any private prescription is issued.
Eligible patients may be able to access private weight management treatment without relying on NHS waiting times. If treatment is prescribed, discreet delivery may also be available.
All treatment is dispensed by our GPhC registered pharmacy in compliance with MHRA regulations.
If you have an existing health condition, take other medicines, or are unsure whether Mounjaro is suitable for you, speak with your doctor or prescriber.
Medical Disclaimer
This page provides general information comparing Mounjaro with alternative weight management options. It is not a substitute for personalised medical advice. Individual results can vary and are not guaranteed. Suitability for any treatment should be confirmed by a prescriber based on your individual medical history, health needs and circumstances.
